Dr. Jinyang Zeng is a Senior Researcher in the Department of Neuropharmacology at the Institute of General Pharmacology and Toxicology, Goethe University Frankfurt. Her research focuses on the systematic investigation of extracellular matrix components, particularly proteoglycans, in renal pathophysiology. Her work explores key mechanisms such as inflammation, innate immunity, autophagy, and fibrosis, with a special emphasis on small leucine-rich proteoglycans (SLRPs), including biglycan, and their roles in kidney diseases.

Beyond renal research, Dr. Zeng has also made significant contributions to immunology and tumor biology. Her interdisciplinary approach bridges fundamental scientific discoveries with clinical applications, particularly in cancer immunotherapy, vaccine development, and translational medicine. She is dedicated to advancing novel strategies for the immunotherapy of malignancies, including lymphoma.

Dr. Zeng serves as a reviewer for numerous prestigious journals, including: The Journal of Biological Chemistry, Matrix Biology, Journal of Histochemistry & Cytochemistry, FASEB BioAdvances, Cellular Signalling, Kidney International, PNAS, and eLife. She also participates in evaluating research grants (e.g., FRS-FNRS, CPI, Danish EOS Foundation) and peer reviews for academic papers and theses. As a world-class scientist and academic leader in cell biology and signal transduction, she has made outstanding contributions to the field.

With over 25 years of experience in academia and the pharmaceutical industry, Dr. Zeng has published more than 30 research articles and contributed to multiple internationally recognized research projects. She has assisted in securing numerous research grants and possesses practical experience in industry collaborations. Additionally, she remains actively involved in scientific publishing, peer review, and mentoring graduate students, consistently driving biomedical advancements to improve patient outcomes.